Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00264914




Registration number
NCT00264914
Ethics application status
Date submitted
12/12/2005
Date registered
13/12/2005
Date last updated
21/01/2009

Titles & IDs
Public title
Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
Scientific title
An Open-Label, Multicenter Study Evaluating the Long-Term Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
Secondary ID [1] 0 0
LTS10208
Secondary ID [2] 0 0
SFY5904
Universal Trial Number (UTN)
Trial acronym
SIADH Safety
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Inappropriate ADH Syndrome 0 0
Hyponatremia 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Other endocrine disorders
Metabolic and Endocrine 0 0 0 0
Other metabolic disorders
Metabolic and Endocrine 0 0 0 0
Diabetes
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - SR121463B

Treatment: Drugs: SR121463B
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety : Physical examination, vital signs, adverse events, electrocardiogram, hematology, serum chemistry
Timepoint [1] 0 0
Secondary outcome [1] 0 0
Serum sodium
Timepoint [1] 0 0

Eligibility
Key inclusion criteria
- Male or female patients aged 18 years and higher.

- SIADH (the diagnosis of SIADH is based on several criteria including true serum
hypoosmolality, inappropriate urinary osmolality, clinical euvolemia, elevated urinary
sodium excretion while on normal salt and water intake, and normal renal, adrenal, and
thyroid functions: drug induced SIADH will be limited to carbamazepine or derivatives
and antidepressants in patients in whom these drugs cannot be discontinued or easily
replaced by other drugs)

- Serum sodium between 115 and 132 mmol/L (at least two consecutive serum sodium levels
of at least 24 hours apart, from Day -6 to Day -1); for sodium levels between 125 and
132 mmol/L, the spontaneous serum sodium increase between the two assessments on Day
-1 should be < 4 mmol/L

- Urinary osmolality >200mOsm/kg H2O

- Urinary sodium > 30 mmol/L
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patients with acute postoperative SIADH

- Presence of dilutional hyponatremia in hypervolemic states such as congestive heart
failure and liver disease with ascites

- Presence of signs of hypovolemia (e.g., orthostatic hypotension, increased serum urea
nitrogen, increased serum albumin, increased hematocrit, …)

- Administration of other V2 receptor antagonists or demeclocycline or lithium within
one month, thiazides diuretics or spironolactone within 15 days, and urea or loop
diuretics within two days prior to study drug administration

- Patients with known treated or untreated adrenal deficiency

- Presence of untreated hypothyroidism

- Presence of uncontrolled diabetes with fasting glycemia > 200 mg/dL (> 11.09 mmol/L)

- Presence of clinical and/or electrocardiographical signs of acute myocardial
infarction or acute ischemia, or any other clinically significant abnormality
according to the Investigator on a 12 lead ECG recording

- Administration of inducers of CYP3A4 (phenytoin, rifampin, Saint John's Wort) or
potent and moderate inhibitor so CYP3A4within two weeks prior to study drug
administration

- Inadequate hematological, renal and hepatic functions; hemoglobin (Hb) < 9 g/dL,
neutrophils < 1,500/mm3, platelets <100,00/mm3, serum creatine >175 µmol/L (or
clearance of creatine <30mL/min for where Ethics Committees require this parameter),
ALT and /or AST >2x upper limit of normal

- QTcB > 500 ms

- Serum potassium > 5 mmol/L

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/07/2005
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/08/2007
Sample size
Target
Accrual to date
Final
57
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Sanofi-Aventis Administrative Office - Macquarie Park
Recruitment postcode(s) [1] 0 0
- Macquarie Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
New Jersey
Country [2] 0 0
Belgium
State/province [2] 0 0
Diegem
Country [3] 0 0
Brazil
State/province [3] 0 0
Sao Paulo
Country [4] 0 0
Canada
State/province [4] 0 0
Laval
Country [5] 0 0
France
State/province [5] 0 0
Paris
Country [6] 0 0
Germany
State/province [6] 0 0
Berlin
Country [7] 0 0
Hong Kong
State/province [7] 0 0
Causeway Bay
Country [8] 0 0
Hungary
State/province [8] 0 0
Budapest
Country [9] 0 0
Russian Federation
State/province [9] 0 0
Moscow
Country [10] 0 0
Switzerland
State/province [10] 0 0
Geneva

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Sanofi
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
To determine the long-term safety and tolerability of SR121463B in patients with syndrome of
inappropriate antidiuretic secretion (SIADH). To assess the long-term efficacy of SR121463B
in maintaining normal levels of serum sodium in patients with SIADH.

Long term safety is evaluated further in an open label extension study with flexible doses of
satavaptan.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00264914
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
ICD CSD
Address 0 0
Sanofi
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00264914